Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 1, 2022

View Archived Issues

OR6A2 is a therapeutic target for atherosclerosis, researchers unveil

Novel ester prodrugs of E-selectin antagonists with improved PK properties

New ENPP2 inhibitors identified at Suzhou Ark Biopharmaceutical

New PROTACs targeting androgen receptors sythesized at Sichuan Haisco Pharmaceutical

Abbisko Therapeutics discovers EGFR inhibtors

Shenzhen Salubris Pharmaceuticals patents ADAM-TS 5 inhibitors

Vitalixir presents new antidiabetic polypeptides

Researchers identify COPA as a prognostic marker and therapeutic target in cervical cancer

Acute intermittent porphyria treatment targets recombinant PBGD protein to the liver

DDO-02005, a novel potent Kv1.5 potassium channel inhibitor with antiarrhythmic activity

Novel CDK9 inhibitor inhibits osteosarcoma in patient-derived orthotopic xenografts

Loss of miR-15a/miR-16-1 contributes to CLL development

Ethris to advance mRNA-based therapeutics for respiratory diseases

Almirall signs agreements with Ablexis and AliviaMab to support work in dermatology

Celsion's DNA-based approach for SARS-CoV-2 vaccine to be studied in NHP challenge study

Drug cocktail is step up for leg regeneration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...